Skip to main content
Premium Trial:

Request an Annual Quote

Cofactor Genomics Raises $18M in Series A Round

NEW YORK (GenomeWeb) – Cofactor Genomics announced today that it has raised $18 million through an oversubscribed Series A financing round.

The round was led by Menlo Ventures, with participation from new and existing investors including Data Collective, Ascension Ventures, iSelect, Y Combinator, Wilson Sonsini Goodrich & Rosati, and Stanford. In connection with the round, Menlo Ventures' Mark Siegel, Data Collective's Matt Ocko, and Ascension's John Kuelper have joined Cofactor's board.

Earlier this year, Cofactor launched Pinnacle, an RNA-based oncology assay that analyzes gene fusions and gene expression in patient tumor samples to provide physicians with potential treatment targets. It is the company's first product following a strategic refocusing onto RNA sequencing and software development. Cofactor is currently preparing to commercialize an immuno-oncology assay called Paragon later this year.

"This financing … is enormous validation of the platform that we've built, and reflects excitement for Cofactor's next phase of growth where we intend to package this expertise in discrete applications that can be easily adopted by research labs and clinical practices throughout the nation," Cofactor CEO Jarret Glasscock said in a statement.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.